S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
Free Trial
CVE:ZOM

Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)
Free ZOM Stock Alerts
C$0.28
-0.02 (-6.56%)
(As of 02/5/2020)
Compare
Today's Range
C$0.29
▼
C$0.29
50-Day Range
C$0.29
▼
C$0.29
52-Week Range
C$0.29
▼
C$1.50
Volume
4,800 shs
Average Volume
2,858 shs
Market Capitalization
C$36.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ZOM stock logo

About Zomedica Pharmaceuticals Corp. (ZOM.V) Stock (CVE:ZOM)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.

ZOM Stock Price History

ZOM Stock News Headlines

November 19, 2023 | morningstar.com
Zomedica Corp Ordinary Shares ZOM
May 10, 2023 | benzinga.com
Zomedica Stock (AMEX:ZOM), Dividends
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
May 8, 2023 | msn.com
Zomedica acquires Structured Monitoring Products
March 15, 2023 | seekingalpha.com
Zomedica expands topline thanks to acquisitions and organic growth
January 25, 2023 | seekingalpha.com
Squarex Pharmaceutical Seeks IPO For Development Funding
January 19, 2023 | marketwatch.com
Advanced Therapy Medicinal Products Market Detailed Analysis of Current Scenario with Growth Forecasts to 2029
January 15, 2023 | marketwatch.com
Pulmonary Edema Treatment Market Opportunities, Demand and Forecasts 2023-2028 with Top Countries Data
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
January 9, 2023 | benzinga.com
Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective of 40+ Companies 2021 v. 2020
December 14, 2022 | wsj.com
HPGC Renmintongtai Pharmaceutical Corp. A
December 14, 2022 | marketwatch.com
Respiratory Devices Market 2023 To Garner Overwhelming Hike In Revenues by 2026 | 132 Pages Report
November 2, 2022 | msn.com
CVS Health raises annual profit forecast on strength in PBM, insurance units
October 6, 2022 | yahoo.com
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
October 1, 2022 | reuters.com
001067F.KS
September 30, 2022 | wsj.com
Saudi Pharmaceutical Industries & Medical Appliances Corp.
September 15, 2022 | finance.yahoo.com
Nova Mentis Completes Production of Psilocybin Microdose Capsules
September 7, 2022 | finance.yahoo.com
Global Counterfeit Drug Detection Devices Market Valuation to Exceed $1.3 Billion by 2026
September 7, 2022 | finance.yahoo.com
Cipla receives USFDA approval for generic version of Revlimid® (Lenalidomide capsules)
August 12, 2022 | finance.yahoo.com
Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 8, 2022 | benzinga.com
Psychedelic Drugs Global Market to Reach $7.03 Billion by 2026
July 15, 2022 | finance.yahoo.com
Insights on the Veterinary Medicine Global Market to 2027 - by Product, Animal Type, Route of Administration, Distribution Channel and Region
July 11, 2022 | finance.yahoo.com
Dilated Cardiomyopathy Market to Boost at a CAGR of approximately 13% by 2032 | DelveInsight
June 29, 2022 | finance.yahoo.com
Global Decentralized Clinical Trials Market is projected to grow at a CAGR of 6.95% By 2032: Visiongain Reports Ltd
June 10, 2022 | apnews.com
The Worldwide Pharmacovigilance Industry is Expected to Reach $15.8 Billion by 2030 - ResearchAndMarkets.com
April 8, 2022 | msn.com
Annapolis Area Job Openings: Check Out The Latest
February 20, 2022 | nz.finance.yahoo.com
PacerPro Director of Design Releases First in a Series of New Product Enhancements
See More Headlines
Receive ZOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
CVE:ZOM
CUSIP
N/A
CIK
N/A
Web
www.zomedica.com
Phone
734-369-2555
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
4.91
Current Ratio
15.31
Quick Ratio
15.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.05 per share
Price / Cash Flow
5.38
Book Value
C$0.05 per share
Price / Book
5.82

Miscellaneous

Outstanding Shares
128,872,000
Free Float
N/A
Market Cap
C$36.73 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Gerald L. Solensky Jr. (Age 45)
    Chairman, Pres & CEO
  • Mr. Shameze Rampertab B.Sc. MBA (Age 52)
    CA, CPA, CFO, Corp. Sec. & Director
  • Dr. Stephanie Morley D.V.M. (Age 44)
    DVM, COO & VP of Product Devel.
  • Mr. Michael Schilk
    VP of Sales
  • Mr. David Eaton
    VP of Marketing

Key Competitors

View All Competitors

ZOM Stock Analysis - Frequently Asked Questions

How have ZOM shares performed in 2024?

Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 at the beginning of the year. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29.
View the best growth stocks for 2024 here.

What other stocks do shareholders of Zomedica Pharmaceuticals Corp. (ZOM.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Heat Biologics (HTBX), Biocept (BIOC), Remark (MARK), Onconova Therapeutics (ONTX), Vislink Technologies (VISL), Genius Brands International (GNUS), Ritter Pharmaceuticals (RTTR), T2 Biosystems (TTOO), Guardion Health Sciences (GHSI) and MicroVision (MVIS).

How do I buy shares of Zomedica Pharmaceuticals Corp. (ZOM.V)?

Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:ZOM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company